Summary:
A Spanish biotech company working in the field of in vitro diagnostic tools for precision medicine, has developed a novel kit which allows a better selection of therapies for patients involved in kidney transplantation processes. The company is growing its product portfolio, developing new selection tools for inflammatory diseases. With the launch of their first renal transplantation product, commercial agency and distribution agreements are sought in EU countries.
Description:
The Spanish biotech company founded in 2015 has succesfully assembled a team of 22 professionals for the development of their solutions regarding precision medicine in vitro diagnostic tools (IVD) for chronic inflammatory conditions.
With successful results in previous R&D stages, their have developed a new diagnostic device that optimizes immunosuppressive therapy for kidney transplant recipients and patients affected by autoimmune diseases. The product already patented, allows physicians to optimize each individual immunosuppressive therapy.
Counting with a proprietary platform their product pipeline comprises other developments for Rheumatoid Arthritis and Lupus Nefritis in the short term, while other organs autoimmune diseases developments are considered in the mid and long terms.
Considering their product commercialization strategy,
internationalization plays an important role, reaching European regional markets through specialized agents has been considered one of their main objectives. Collaborations are sought preferably under commercial agreements or distribution services agreements.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The company seeks EU distributors with expertise and established networks for in vitro diagnosis kits. The company wants the partner to contribute with their knowledge of channels and actors at regional/national level, for the development of links with the different clients and customers (hospital, clinic labs, pharmacies) needs and requirements (regulatory and/or logistics). Collaborations are preferably sought preferably under commercial agency or distribution services agreements.
Stage of Development:
Available for demonstration
Comments Regarding Stage of Development:
The product has completed national an international clinical studies. CE Mark approval 4Q2021.
IPR Status:
Patents granted
Comments Regarding IPR Status:
Patent granted in EU and USA. Increasing countries applications have been planned following their IP strategy.
External code:
BOES20211011001
